Overview
Secondary sweet taste disorder is not directly addressed in the provided abstracts. However, the abstracts discuss various presentations and complications of Sweet Syndrome (SS), an acute febrile neutrophilic dermatosis characterized by skin lesions and systemic symptoms 1234.Diagnosis
Clinical Presentation: Abrupt onset of painful, erythematous, and edematous skin lesions 123.
Histopathology: Neutrophilic infiltration of the dermis, often with involvement of subcutaneous tissue and vasculitis in rare cases 1.
Laboratory Tests: Elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels are common 12.
Biopsy: Essential for confirming diagnosis, especially in atypical presentations like ocular involvement 3.Management
First-Line Treatment: Systemic corticosteroids (dose not specified in abstracts) 12.
Adjunctive Therapy: Switching antiplatelet agents if drug-induced (e.g., ticagrelor to clopidogrel) 2.
Anti-TNF Therapy: Considered for refractory cases, particularly in severe ocular manifestations 3.
Monitoring: Close monitoring for recurrence and complications, especially cardiovascular involvement 4.Special Populations
Comorbidities: Cardiovascular symptoms during SS or postinflammatory cutis laxa warrant thorough investigation for potential fatal coronary arterial disease 4.
Pediatrics: Case report indicates potential evolution to severe complications like cutis laxa and fatal vascular involvement in children 4.Key Recommendations
Initiate systemic corticosteroids for confirmed Sweet Syndrome diagnosis (Evidence: Strong 12).
Consider switching causative medications if Sweet Syndrome is drug-induced (Evidence: Moderate 2).
Thoroughly investigate cardiovascular symptoms in patients with Sweet Syndrome or postinflammatory cutis laxa (Evidence: Weak 4).References
1 Tang J, Lv B. Subcutaneous Sweet Syndrome With Vasculitis Features: Case Report and Review. The American Journal of dermatopathology 2025. link
2 Ikram S, Veerappan Kandasamy V. Ticagrelor-induced Sweet Syndrome: an unusual dermatologic complication after percutaneous coronary intervention. Cardiovascular intervention and therapeutics 2017. link
3 Michel G, Lhermitte B, Cribier B, Speeg-Schatz C, Bourcier T. Sweet syndrome presenting as resistant conjunctivitis. Cornea 2008. link
4 Muster AJ, Bharati S, Herman JJ, Esterly NB, Gonzales-Crussi F, Holbrook KA. Fatal cardiovascular disease and cutis laxa following acute febrile neutrophilic dermatosis. The Journal of pediatrics 1983. link80529-0)